The single pregnancy predicting model of 1 minute Apgar score less than 7 after preterm birth: A retrospective study.

Preterm delivery is greatly associated with perinatal mortality and morbidity, while there is no objective way to identify high-risk newborns currently. This study aimed at discovering the risk factor for Apgar score less than 7 at 1 minute of preterm neonates born with vaginal delivery. A retrospective study was performed in single pregnancy women with a vaginal delivery before 37 weeks of gestation. All the preterm infants were categorized into three types: very preterm birth (28 to 32 weeks), moderate preterm birth (32 to 34 weeks) and late preterm birth (34 to 37 weeks). Risk factors were identified through logistic regression analysis in every category of newborns mentioned above. And the receiver operating characteristic analysis was used in continuous variables to determine the best threshold of the outcome. On the basis of the selected factors, the predicting models are created and its prognosticating ability is compared by the area under the curve. A nomogram was established for the proved best model. A total of 981 cases were investigated, of whom 55 were found with 1 min Apgar scores less than 7. The nomogram was set for the predicting model with larger area under the receiver operating characteristic curve, of which is 0.742(95% confidence interval = 0.670-0.805) in very preterm birth, with the variables of first and second labor stage(> = 1.6 hours), birthweight and MgSO4(magnesium sulfate), and is 0.807(95% confidence interval = 0.776-0.837) in late preterm birth, with the variables of second labor stage(> = 1.23 hours), birthweight, a history of previous cesarean delivery, fetal distress and placental abruption. The combination of first and second labor stage, newborn weight and MgSO4 use can predict 74.2% of 1 minute Apgar score < 7 in very preterm neonates. And 80.7% high-risk infants can be identified when second labor stage, newborn weight, VBAC (vaginal birth after cesarean) and the occur of placental abruption and fetal distress were combined in the predicting model for late preterm birth. These predicting models would bring out great assistance towards obstetricians and reduce unnecessary adverse fetal outcomes.

Evaluation of the inhibitory effect of tripeptide tyroservatide on growth of human hepatocellular carcinoma using a hollow fiber assay / 中华肿瘤杂志

<p><b>OBJECTIVE</b>To investigate the inhibitory effect of tyroservatide (YSV) on growth of hepatocellular carcinoma cells.</p><p><b>METHODS</b>In vitro effects of YSV on five human hepatocellular carcinoma cell lines were assayed by MTS. In vivo effects of YSV on 5 human hepatocellular carcinoma cell lines were assayed by hollow fiber tumor model.</p><p><b>RESULTS</b>After treatment with YSV at a dose of 0.1 approximately 1.6 mg/ml, the growth of the five cell lines was significantly inhibited in vitro compared with that of the control group (P < 0.05). Especially, YSL remarkably inhibited the growth of human hepatocellular carcinoma BEL-7402 cells, i.e. the cell growth was inhibited by 63.3% after treatment with YSL at 1.6 mg/ml. The hollow fiber tumor model demonstrated that YSL (320 microg x kg(-1) x d(-1) and 640 microg x kg(-1) x d(-1)) treatment significantly inhibited the in vivo growth of the five cancer cell lines compared with that in the saline control (P < 0.05). YSL showed the highest level of inhibition of human BEL-7402 hepatocellular carcinoma cells, with an inhibitory index of 53.1% at 320 microg x kg(-1) x d(-1).</p><p><b>CONCLUSION</b>As a new method, hollow fiber assay may be used to evaluate the inhibitory effect of drugs on different tumor cells in vivo, rapidly, accurately and economically. Our results provide an instruction and evidence for clinical use of YSV.</p>

Tyroservatide inhibits the growth of human hepatocarcinoma in nude mice / 中华肿瘤杂志

<p><b>OBJECTIVE</b>To investigate the inhibitory effects of tyroservatide and its amino acid mixture on growth of hepatocarcinoma.</p><p><b>METHODS</b>Hepatocarcinoma in nude mice was induced by implantation of cells of human hepatocarcinoma cell line BEL-7402. The inhibition of hepatocarcinoma growth was determined by calculating the tumor volume and measuring the tumor weight. The effects of tyroservatide on tumor cells in nude mice were assessed by immunohistochemical staining of proliferating cell nuclear antigen (PCNA), electron microscopic observation of ultrastructure, and apoptosis of tumor cells using terminal deoxynucleotidyl transferase biotin-dUTP nick end labeling (TUNEL).</p><p><b>RESULTS</b>Tyroservatide significantly inhibited the growth of human hepatocarcinoma in nude mice, with an inhibiting rate more than 60%. But the mixture of amino acid did not show a significant inhibitory effect on the tumor growth. Tyroservatide also induced apoptosis of tumor cells and decreased the expression of PCNA in tumor cells.</p><p><b>CONCLUSION</b>Tyroservatide may significantly inhibit the growth of human hepatocarcinoma in nude mice by inducing apoptosis and inhibiting proliferation of tumor cells.</p>